Human iPSC-derived neurons

Consistent, defined and scalable human iPSC-derived neurons for neurodegeneration, neurophysiology, and neurodevelopmental research

Nerve cells, also known as neurons are the fundamental units of the brain and nervous system, responsible for receiving and transmitting information throughout the body. Rich with multiple neuronal cell types and varied glial cells, neural tissue has historically been difficult to model in vitro [1]. Such modelling challenges greatly slow our progress in understanding and treating neurodegenerative disease. Fortunately, this is changing with recent advances in induced pluripotent stem cell (iPSC) technology. 

bit.bio’s deterministic cell programming technology (known as opti-ox™) enables the rapid conversion of entire cultures of stem cells into a precise cell identity with unprecedented consistency. The rapid gain of functionality of bit.bio’s human nerve cells empower researchers to build the types of physiologically relevant in vitro models needed to drive research into neurodegenerative disease and neuropsychiatric disorders, and the data-backed lot-to-lot consistency enables standardisation across assays used in early stages of drug discovery, from target identification to clinical translation.

Additionally, the development of CRISPR-Ready neurons makes it possible to perform functional genomic screening in human iPSC-derived neurons, opening the door to more efficient and physiologically relevant target identification and validation studies. Unlike primary neurons that often lack suitable controls, our range of ioCells includes disease models with engineered disease-specific mutations and genetically matched controls. Having access to defined, human iPSC-derived neurons that emulate neurodegenerative disease will help accelerate progress in understanding and ultimately treating these devastating diseases.  

Elevate your research with bit.bio’s human iPSC-derived neurons, from CRISPR-Ready glutamatergic neurons to ALS-specific motor neurons.

ioWild Type Cells

ioWild Type Cells

ioGABAergic Neurons

cat no | io1003

ioWild Type Cells

ioGlutamatergic Neurons

cat no | io1001

ioWild Type Cells

ioSensory Neurons

cat no | io1024

ioWild Type Cells

ioMotor Neurons

cat no | io1027

Engineered to meet your workflow with our toolkit of ioDisease Model Cells, ioTracker Cells and CRISPR-Ready ioCells

See all neuronal cell products

CRISPR-Ready ioCells

CRISPRko-Ready ioGlutamatergic Neurons

cat no | io1090

ioDisease Model Cells

ioGABAergic Neurons APP V717I/WT

cat no | io1085

ioDisease Model Cells

ioMotor Neurons TDP-43 M337V/WT

cat no | io1050

ioTracker Cells

GFP ioMotor Neurons

cat no | io1112

ioDisease Model Cells

ioMotor Neurons TDP-43 M337V/M337V

cat no | io1046

ioDisease Model Cells

ioGlutamatergic Neurons HTT 50CAG/WT

cat no | ioEA1004

ioDisease Model Cells

ioMotor Neurons SOD-1 G93A/WT

cat no | io1042

ioDisease Model Cells

ioMotor Neurons SOD-1 G93A/G93A

cat no | io1041

ioDisease Model Cells

ioGABAergic Neurons APP V717I/V717I

cat no | io1082

ioDisease Model Cells

ioMotor Neurons FUS P525L/WT

cat no | io1055

ioDisease Model Cells

ioMotor Neurons FUS P525L/P525L

cat no | io1052

ioDisease Model Cells

ioMotor Neurons TDP-43 A382T/WT

cat no | io6019

ioDisease Model Cells

ioMotor Neurons TDP-43 N352S/WT

cat no | io6017

ioDisease Model Cells

ioGlutamatergic Neurons TDP-43 M337V/M337V

cat no | ioEA1005

ioDisease Model Cells

ioGlutamatergic Neurons TDP-43 M337V/WT

cat no | ioEA1006

ioDisease Model Cells

ioGlutamatergic Neurons PRKN R275W/WT

cat no | io1013

ioDisease Model Cells

ioGlutamatergic Neurons PRKN R275W/R275W

cat no | io1020

ioDisease Model Cells

ioGlutamatergic Neurons SNCA A53T/A53T

cat no | io1088

ioDisease Model Cells

ioGlutamatergic Neurons SNCA A53T/WT

cat no | io6005

ioDisease Model Cells

ioGlutamatergic Neurons PSEN1 M146L/M146L

cat no | io1069

ioDisease Model Cells

ioGlutamatergic Neurons PSEN1 M146L/WT

cat no | io1072

ioDisease Model Cells

ioGlutamatergic Neurons APP V717I/WT

cat no | io1067

ioDisease Model Cells

ioGABAergic Neurons APP V717I/V717I

cat no | io1082

ioDisease Model Cells

ioGlutamatergic Neurons APP KM670/671NL/WT

cat no | io1061

ioDisease Model Cells

ioGlutamatergic Neurons APP V717I/V717I

cat no | io1063

ioDisease Model Cells

ioGlutamatergic Neurons GBA null/R159W

cat no | io1007

CRISPR-Ready ioCells

CRISPRa-Ready ioGlutamatergic Neurons

cat no | io1099

CRISPR-Ready ioCells

CRISPRi-Ready ioGlutamatergic Neurons

cat no | io1098

ioTracker Cells

GFP ioGlutamatergic Neurons

cat no | io1107

Producing 3D Neuronal Microtissues for Preclinical Drug Screening using ioGlutamatergic Neurons

Dive into this application note, to discover how ioGlutamatergic Neurons and iPSC-derived astrocytes have been used in 3D microtissues, to build a powerful model system for medium- to high-throughput drug screening and more productive preclinical drug development.

Download application note

Product resources

User manual

CRISPRko-Ready ioMotor Neurons

Access now

Webinar

Modelling neurodevelopment | Investigating the impact of maternal immune activation on neurodevelopment using human iPSC-derived cells

Prof Deepak Srivastava | King’s College London

Watch now

Webinar

Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming

Ania Wilczynska, PhD | bit.bio

Watch now

Webinar

Mastering Cell Identity In A Dish: The Power Of Cellular Reprogramming

Prof Roger Pedersen | Stanford University 

Thomas Moreau, PhD | bit.bio

Watch now

Webinar

Running Large-Scale CRISPR Screens in Human Neurons

Emmanouil Metzakopian | bit.bio

Javier Conde-Vancells | bit.bio

Watch now

Webinar

Empowering motor neuron disease research and drug discovery with a new class of functional, reproducible hiPSC-derived motor neurons

Tom Brown | bit.bio

Marcos Herrera Vaquero, PhD | bit.bio

Watch now

Webinar

Human iPSC-Based Models of Glial Cells for Studying Neurodegenerative Disease

Valentina Fossati, PhD | The New York Stem Cell Foundation

Inês Ferreira | bit.bio

Watch now

Webinar

Harnessing AI-guided visual biology to discover drug targets for neurodegenerative disease

Ben Bar-Sadeh, PhD | Anima Biotech

Tom Brown | bit.bio

Watch now

Frequently Asked Questions (FAQs)

 

• Which human iPSC-derived neuron types are available within bit.bio’s portfolio?

The bit.bio ioCells portfolio includes human iPSC-derived GABAergic, Glutamatergic, Motor, and Sensory Neurons. Powered by opti-ox technology, these cryopreserved, post-mitotic cells offer unmatched lot-to-lot consistency at scale, enabling standardisation across research and drug discovery workflows.

 

• How do these ioCells support disease modelling?

Unlike primary neurons that often lack suitable controls, bit.bio’s ioCells portfolio includes ioDisease Model Cells engineered with disease-relevant mutations for conditions such as ALS, Alzheimer’s, and Parkinson’s disease, these can be paired with genetically matched ioWild Type Cells to enable true experimental comparisons. Access to defined human neurons enables scientists to study neurodegenerative disease in a human physiologically relevant context.

 

• Can ioCells neurons be used to build complex models? 

The ioCells portfolio of human iPSC-derived glutamatergic, GABAergic, sensory and motor neurons rapidly gain functionality and are ideal for building physiologically relevant in vitro models. They can be co-cultured with glial cells and other neuronal subtypes to simulate the complex networks needed to drive research into neurodegenerative and neurological disorders.

References

1. Pereira I, Lopez-Martinez MJ, Samitier J. (2023) Advances in current in vitro models on neurodegenerative diseases. Front. Bioeng. Biotechnol. doi: 10.3389/fbioe.2023.1260397.

Related pages

Glial cells Explore our range of hiPSC-derived glial cells

Muscle cells Explore our range of hiPSC-derived muscle cells

Contact us Talk to us about how our technology could support your cell therapies